P998 BENEFIT OF SORAFENIB ACCORDING TO UNDERLYING LIVER DISEASE ETIOLOGY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

M. Bouattour, N. Goutte, M.-P. Vullierme, C. Castelnau, O. Farges, S. Faivre, F. Durand, L. Castera
  • Journal of Hepatology, April 2014, Elsevier
  • DOI: 10.1016/s0168-8278(14)61158-2
The author haven't finished explaining this publicationThe author haven't finished explaining this publication

The following have contributed to this page: Dr Mohamed Bouattour